药物评价研究2024,Vol.47Issue(1) :197-203.DOI:10.7501/j.issn.1674-6376.2024.01.024

乌药提取物及有效成分抗肝损伤的药理作用研究进展

Research progress on anti-hepatic injury effects of extracts of Lindera aggregata and its active components

欧阳婷 刘涛 欧阳林旗
药物评价研究2024,Vol.47Issue(1) :197-203.DOI:10.7501/j.issn.1674-6376.2024.01.024

乌药提取物及有效成分抗肝损伤的药理作用研究进展

Research progress on anti-hepatic injury effects of extracts of Lindera aggregata and its active components

欧阳婷 1刘涛 2欧阳林旗3
扫码查看

作者信息

  • 1. 湖南中医药大学第一附属医院,湖南长沙 410007
  • 2. 长沙市第一医院,湖南长沙 410005
  • 3. 湖南中医药大学第一附属医院,湖南长沙 410007;湖南中医药大学药学院,湖南长沙 410208
  • 折叠

摘要

乌药为樟科山胡椒属植物乌药Lindera aggregata(Sims)Kosterm.的干燥块根,主要成分包括倍半萜类、生物碱类、黄酮类和挥发油等,具有抗氧化、抑菌、抗炎镇痛、抗肿瘤等多种药理作用.近年,诸多研究表明乌药对酒精性肝损伤、化学性肝损伤、免疫性肝损伤、糖尿病合并肝损伤、脂肪肝、肝癌等肝脏相关疾病都有防治作用.综述了乌药水提取物、醇提取物、醇提取物的萃取物、叶提取物、根挥发油及乌药醚内酯抗肝损伤的药理作用及研究现状,以期为后续乌药相关保肝药物的开发及利用提供理论基础.

Abstract

Lindera aggregata was the dried root tubers of Lindera aggregata(Sims)Kosterm.The main components include sesquiterpenoids,alkaloids,flavonoids and volatile oils,which have various pharmacological effects such as antioxidant,antibacterial,anti-inflammatory and analgesic,and anti-tumour.In recent years,many studies have shown that Lindera aggregata has been effective against alcoholic liver injury,chemical liver injury,immune liver injury,diabetes combined with liver injury,fatty liver,liver cancer and other liver-related diseases.This article reviewed the pharmacological effects on liver injury and research status of water extract,alcohol extract,various extracts of alcohol extract,leaf extract,volatile oil of Lindera aggregata and linderane,providing a theoretical basis for the subsequent development and utilization of Lindera aggregata related drugs.

关键词

乌药/乌药醚内酯/肝损伤/脂肪肝/肝癌/作用机制

Key words

Lindera aggregata(Sims)Kosterm/linderane/liver injury/fatty liver/liver cancer/mechanism

引用本文复制引用

基金项目

湖南省自然科学基金资助项目(2020JJ5434)

湖南省卫生健康委科研项目(C202313057956)

湖南省卫生健康委科研项目(D202302048806)

湖南中医药大学校级科研基金(2019XJJJ033)

湖南中医药大学校级科研基金(2021XJJJ040)

湖南中医药大学校级科研基金(2022XYLH004)

湖南省"十四五"中医重点专科资助项目(湘中医药函[2023]4号)

出版年

2024
药物评价研究
天津药物研究院 中国药学会

药物评价研究

CSTPCD北大核心
影响因子:1.199
ISSN:1674-6376
参考文献量18
段落导航相关论文